Laser treatment of benign prostatic hyperplasia (BPH) reimbursed in Japan:
This article was originally published in Clinica
Executive Summary
Sales of Trimedyne's lasers are expected to expand "significantly" now that the Japanese Ministry of Health and Welfare has approved reimbursement for the use of lasers to treat benign prostatic hyperplasia. Approved for marketing in Japan last year, the holmium laser is distributed in Japan by Meditec, a subsidiary of Marubeni. The reimbursement rate of $2,400 set by the Japanese Ministry includes hospital charges and the cost of the laser fibre.